Skip to content

Study · Randomized controlled trial · n = 468 · 2020

9 results

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.

van der Aart-van der Beek AB, van Raalte DH, Guja C, Hoogenberg K, Suchower LJ, Hardy E, Sjöström CD, Heerspink HJL

Diabetes, obesity & metabolism29 May 2020Cited by 25 (Europe PMC)

PMID32329160 (opens in a new tab)PMCIDPMC7496075 (opens in a new tab)DOI10.1111/dom.14067 (opens in a new tab)PepBankPUB-32329160
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and elevated albuminuria, weekly exenatide reduced albuminuria versus pooled comparators.

    In plain wordsIn patients with diabetes and elevated urine albumin, weekly exenatide reduced albuminuria more than pooled comparator treatments.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAlbuminuria
    Study

    n = 468

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Measurements

    Albuminuria relative change
    −26.2%
    versus pooled comparators

    Source sentences

    Summary
    Relative to the comparator group, EQW changed albuminuria by -26.2% (95% confidence interval [CI] -39.5 to -10).
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and elevated albuminuria, weekly exenatide reduced HbA1c more than pooled comparators.

    In plain wordsIn patients with diabetes and elevated urine albumin, weekly exenatide reduced HbA1c more than pooled comparators.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c
    Study

    n = 468

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Source sentences

    Summary
    Adjusted mean decreases in HbA1c, SBP and body weight were more pronounced in the EQW versus the comparator group.
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and elevated albuminuria, weekly exenatide reduced systolic blood pressure more than pooled comparators.

    In plain wordsIn patients with diabetes and elevated urine albumin, weekly exenatide reduced systolic blood pressure more than pooled comparators.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 468

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Source sentences

    Summary
    Adjusted mean decreases in HbA1c, SBP and body weight were more pronounced in the EQW versus the comparator group.
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and elevated albuminuria, weekly exenatide reduced weight more than pooled comparators.

    In plain wordsIn patients with diabetes and elevated urine albumin, weekly exenatide reduced weight more than pooled comparators.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 468

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Source sentences

    Summary
    Adjusted mean decreases in HbA1c, SBP and body weight were more pronounced in the EQW versus the comparator group.
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and elevated albuminuria, weekly exenatide reduced albuminuria versus oral glucose-lowering drugs.

    In plain wordsIn patients with diabetes and elevated urine albumin, weekly exenatide reduced albuminuria more than oral glucose-lowering drugs.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAlbuminuria versus oral drugs
    Study

    n: not reported in source

    Comparator
    Oral glucose-lowering drugs
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Measurements

    Albuminuria relative change
    −29.6%
    versus oral glucose-lowering drugs

    Source sentences

    Summary
    Similar improvements were observed with EQW versus oral glucose-lowering drugs (-29.6% [95% CI -47.6 to -5.3) or insulin (-23.8% [95% CI -41.8 to -0.2]).
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and elevated albuminuria, weekly exenatide reduced albuminuria versus insulin.

    In plain wordsIn patients with diabetes and elevated urine albumin, weekly exenatide reduced albuminuria more than insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAlbuminuria versus insulin
    Study

    n: not reported in source

    Comparator
    Insulin
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Measurements

    Albuminuria relative change
    −23.8%
    versus insulin

    Source sentences

    Summary
    Similar improvements were observed with EQW versus oral glucose-lowering drugs (-29.6% [95% CI -47.6 to -5.3) or insulin (-23.8% [95% CI -41.8 to -0.2]).
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and elevated albuminuria, the weekly exenatide uACR effect was independent of baseline renin-angiotensin inhibitor use.

    In plain wordsIn patients with diabetes, baseline renin-angiotensin inhibitor use did not explain weekly exenatide's urine albumin effect.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableuACR effect by baseline renin-angiotensin inhibitor use
    Study

    n: not reported in source

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Source sentences

    Summary
    The effect of EQW on uACR was independent of baseline renin-angiotensin system inhibitor usage.
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, adjustment for HbA1c, eGFR and SBP changes did not substantially affect weekly exenatide's uACR-lowering effect.

    In plain wordsIn patients with diabetes, adjustment for glucose, kidney filtration and blood pressure changes did not substantially change exenatide's urine albumin effect.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseuACR after HbA1c, eGFR and SBP adjustment
    Study

    n: not reported in source

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Source sentences

    Summary
    Adjustment for changes in HbA1c, eGFR and SBP did not substantially affect the uACR-lowering effect of EQW.
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, additional weight-change adjustment attenuated weekly exenatide's uACR effect, with the confidence interval crossing zero.

    In plain wordsIn patients with diabetes, additional weight adjustment weakened exenatide's urine albumin effect, with the interval crossing zero.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeuACR after additional weight adjustment
    Study

    n: not reported in source

    Comparator
    All non-GLP-1 receptor agonist comparators pooled
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26/28 weeksAs given in this study (human).

    Measurements

    Adjusted uACR effect
    −13%
    after additional body weight adjustment

    Source sentences

    Summary
    When also adjusting for changes in body weight, the uACR-lowering effect was reduced to (-13.0% [95% CI -29.9 to 7.8]).
    2 context sentences
    Summary · context
    Six randomized double-blind and open-label phase III studies were pooled in a post hoc, exploratory analysis to evaluate the efficacy and safety of EQW versus non-glucagon-like peptide-1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g.
    Summary · context
    Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.